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Background: Gold coating improves stent visibility under fluoroscopy. This is particularly valuable for precise stent
placement during renal artery stenting (RAS). There is conflicting evidence regarding restenosis with gold-coated stents.
To evaluate the effect of gold coating on restenosis after renal stenting, we reviewed the results of all patients undergoing
RAS in our practice.
Methods: A retrospective cohort study of all patients undergoing RAS between June 2000 and September 2003 was
performed. During this time, both gold-coated and stainless steel stents were used. Restenosis (>60% diameter) was
determined by serial follow-up duplex exams (peak systolic velocity >180cm/s and renal-aortic ratio >3.5). Restenosis
rates were determined by using the Kaplan-Meier life-table method. Variables potentially affecting restenosis were
evaluated with the log-rank test and Cox proportional hazards modeling.
Results: RAS was performed in 97 arteries (78 patients). Gold-coated (NIRoyal) stents were placed in 59 arteries (48
patients). Stainless steel stents (Corinthian, Genesis, and Herculink) were placed in 38 arteries (34 patients). Patient
demographics, indication for treatment, technical success, and complications did not differ between gold and stainless
steel stent groups. Mean follow-up was 15 months for gold-coated stents and 18 months for stainless steel stents (NS).
By life-table method, 1-year and 2-year freedom from restenosis rates were 84% and 78% in arteries treated with stainless
steel stents versus 69% and 39% in those treated with gold-coated stents (P  .012, log-rank test). By multivariate
analysis, only the use of gold-coated stents (P  .018; hazard ratio [HR], 3.3; 95% confidence interval [CI], 1.2 to 8.7)
and bilateral disease (P .046; HR, 2.3; 95%CI, 1.02 to 5.2) predicted restenosis. Stent diameter, patient demographics,
and indication for RAS had no effect on restenosis by univariate analysis. According to American Heart Association
criteria, 87% of patients in the stainless steel group had improved blood pressure at 1 year, compared with 77% in the
gold-coated stent group (Kaplan-Meier; P  .042, log-rank test). There were no significant differences in the effect of
RAS on serum creatinine levels between the two groups.
Conclusion: Gold-coated renal stents had a substantially higher rate of restenosis than stainless steel stents in our series.
These findings have led us to abandon the use of gold-coated stents for RAS. Patients who have received gold-coated
stents for the treatment of atherosclerotic renal artery stenosis should be followed closely for evidence of restenosis.
(J Vasc Surg 2005;42:40-6.)Renal artery percutaneous transluminal angioplasty
(RPTA) was introduced by Gruntzig in 1978.1 Initial
reports demonstrated an improvement in blood pressure
control in patients with renovascular hypertension and
renal function in patients with chronic renal insuffi-
ciency.2-4 The technical success of RPTA was poor, how-
ever, and 1-year restenosis was 27% to 100%.5
Metallic stents were introduced for the treatment of renal
artery stenosis in 1991.6 Compared with RPTA, renal artery
stenting (RAS) has since been shown to improve technical
success; however, restenosis rates remainwidely variable, from
13% to 43% at 1 year.7-12 Stent design has continued to evolve
during the last 2 decades in an attempt to improve technical
success and reduce complication and restenosis rates.
In 1996, gold-coated stents became available for clinical
use in the coronary circulation.13 Gold coating made stents
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40more radio-opaque to enhance visibility under fluoroscopy.
These stents subsequently became popular for use in the renal
artery, where precise stent placement is required for the treat-
ment of atherosclerotic ostial stenosis. Along with superior
visibility, preliminary animal studies also suggested that gold
might reduce the incidence of acute stent thrombosis. 14
Clinical evidence from the coronary circulation, how-
ever, has indicated that gold-coated stents have a higher
rate of in-stent restenosis secondary to intimal hyperplasia.
Three prospective, randomized trials comparing gold-
coated and noncoated stents used in coronary arteries
demonstrated a higher rate of restenosis in gold-coated
stents.15-17 This problem has not been widely studied for
RAS. A single retrospective analysis showed no difference
between restenosis in gold-coated and stainless steel stents
used to treat renal artery stenosis.18 The purpose of the this
study was to analyze our experience with restenosis in
gold-coated versus stainless steel stents used in the treat-
ment of renal artery stenosis.
METHODS
Patients and indications. All patients with athero-
sclerotic renal artery stenoses who underwent RAS by vas-
cular surgeons at Dartmouth-Hitchcock Medical Center
between June 2000 and September 2003 were reviewed. A
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low-up data collected through September 2004. Four pa-
tients (5%) were treated with a gold-coated stent on one
side and stainless steel stent on the other. Clinical outcomes
data (blood pressure and serum creatinine values) from
these four patients were omitted from analysis, but stent
restenosis data was included.
All patients with bilateral disease who were treated with
the same stent type were treated either during the same
procedure or within several days to weeks after. Staged
treatment was done to minimize contrast exposure. These
patients all had an initial diagnosis of bilateral disease (ie,
none had a renal artery stenosis detected during follow-up
of a contralateral stent). Clinical outcomes and restenosis
data in patients with bilateral disease treated with the same
type of stent were therefore included in the analysis.
Patients with a clinical indication for treatment of renal
artery stenosis were selected in accordance with the Amer-
ican Heart Association (AHA) guidelines.19,20 Indications
included (1) renovascular hypertension either resistant to
treatment with at least three medications of different classes
or associated with medication intolerance or a solitary
kidney, (2) chronic renal insufficiency (serum creatinine
’1.4 mg/dL) of unknown etiology, or both.
Arteriography was performed on patients with a clinical
indication for therapy in whom a stenosis was identified by
duplex scan (peak systolic velocity 200 cm/s or renal-
aortic ratio 3.5).21 Patients with renal insufficiency were
pretreated with 600 mg oral N-acetylcysteine twice the day
before the procedure and again on the day of the proce-
dure.
Criteria for therapy at angiography was a systolic pres-
sure gradient15 mmHg or a75% stenosis. High-grade
stenoses (75% diameter reduction) were stented without
measuring a pressure gradient to reduce the risk of embo-
lization. Occluded arteries were revascularized if the ipsi-
lateral kidney was not atrophic (9 cm) and there was
evidence that the occlusion was relatively acute (ie, artery
patent by preoperative imaging found to be occluded at
angiography). Bilateral disease was defined as a right and
left renal artery stenosis meeting criteria for therapy or a
renal artery stenosis meeting the indications for therapy
with a contralateral renal artery occlusion.
Stent selection. During the 3 years studied, three
discrete periods occurred during which three types of low
profile (0.014” or 0.018” platform) balloon expandable
stents were deployed:
● The initial 25 arteries were treated with “over the
wire” (OTW) stainless steel stents, either Corinthian
or Herculink (Guidant).
● The next 59 arteries were treated with OTW, NIRoyal
gold-coated stents (Boston Scientific Corp). The NI-
Royal stent became the stent of choice because of its
superior visualization that made it technically easier to
use and more accurate for the treatment of ostial
stenoses.● The final 13 arteries reported in this series were treated
with a Genesis monorail, stainless steel stent (Cordis).
The change back to a stainless steel stent was because
of its availability in the monorail platform, making it
easier to use with the PercuSurge Guardwire
(Medtronic) embolic protection device.
Although the type of stent deployed changed with
time, all surgeons in the group used the same type of stent
during each given time period.
Technique. Percutaneous access was obtained through
the common femoral artery unless contraindicated by occlu-
sive or aneurysmal disease, in which case a left brachial ap-
proach was used. A micropuncture technique (20-gauge ac-
cess needle, 0.018-in wire and 5F sheath) was used to
minimize access trauma. A 0.035-in guidewire was advanced
under fluoroscopic guidance (OEC 9800, 12-in image inten-
sifier or fixed GE system, 16-in image intensifier) into the
abdominal aorta. Diagnostic arteriography was performed
through a 5F flush catheter. If a renal artery stenosis was
confirmed, a 6F left internalmammary artery guiding catheter
was positioned at the origin of the renal artery over the
0.035-in wire, taking care not to occlude or touch the orifice
of the artery. Intravenous heparin (100 U/kg) was adminis-
tered. The renal artery was selected and the lesion crossed by
using a 0.014-in or a 0.018-in wire.
Embolic protection was employed selectively by using
the 0.014-in Guardwire temporary balloon occlusion and
aspiration system. Indications for embolic protection were
a serum creatinine level of 2.0 mg/dL, or a solitary
kidney, or both.
Critical lesions (75%) were predilated with a low-
profile balloon (3  20 mm). Atherosclerotic lesions were
then preferentially treated with balloon-expandable stents.
After deployment, a pressure measurement was obtained
across the stent using a 4F glide catheter. If a residual
gradient 5 mm Hg was present, it was localized then
treated with either angioplasty or a second stent. Technical
adequacy (stenosis 30%) was also assessed by arteriogra-
phy.
Postoperatively, all patients were given a 300-mg load-
ing dose of Plavix (Bristol-Myers Squibb Co) and treated
for 1 month with a standard 75-mg dose along with 325
mg of aspirin.
Outcomes. Surveillance renal duplex for restenosis
was performed 1 month after the procedure and every 3 to
6 months thereafter. Velocity criteria for restenosis were a
peak systolic velocity 180 cm/s and renal-aortic ratio
3.5 on follow-up exam.9 Indications for follow-up arte-
riogram in patients with velocity elevations by duplex scan
included recurrent hypertension or worsening renal func-
tion, the presence of a solitary kidney, or clear progression
of restenosis determined by subsequent duplex exams. Pa-
tients with recurrent stenosis by duplex exam but no other
indication for treatment were followed with duplex ultra-
sound scanning until an indication developed.
Clinical measures of blood pressure and renal function
are reported at last follow-up (1-year mean) in accordance
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fined as a diastolic pressure90 or systolic pressure140,
or both, on the same or a reduced number of medications.
Inability to meet these criteria was defined as failure. Im-
proved renal function was defined as a decrease in serum
creatinine levels 20% relative to baseline. Renal function
was considered stable if the creatinine remained 20% of
baseline and worse if it was increased by 20%.
Statistical analysis. Dichotomous variables are pre-
sented as proportions and compared with the 2test. Con-
tinuous variables are presented as mean  standard devia-
tion and compared with the Student’s t test. Predictors of
restenosis were determined by Cox regression with univar-
iate and multivariate analysis. Hypertension response, renal
function response, and restenosis rates were analyzed by
using Kaplan-Meier life-table methods. Comparisons of
these outcomes between groups were made with the log-
rank test. P  .05 was considered statistically significant.
RESULTS
Ninety-seven arteries were treated for atherosclerotic
occlusive disease (3 occlusions, 94 stenoses). Gold-coated
stents were used to treat 59 arteries in 48 patients, and 38
arteries in 34 patients received stainless steel stents. Four
patients with bilateral disease received both a steel and
gold-coated stent. Overall, 50% of patients were treated for
renovascular hypertension and 50% for chronic renal insuf-
ficiency. Patient demographics and indication for treatment
did not differ between gold-coated and stainless steel stent
groups (Table I). Duplex and angiographic findings also
did not differ statistically between groups (Table II).
Primary technical success was achieved in 92 patients
(95%) and did not differ by stent group. Technical failure in
the remaining five patients was because of an inability to
Table I. Demographics and indications for patients
undergoing renal stent placement according to stent
type—gold-coated or stainless steel
Gold (n  44)% Steel(n  30)% P
Age (years) 69  10 67  15 .74
Female gender 43 50 .72
Diabetes 18 20 .93
















Hypertension 50 53 .79
Chronic renal
insufficiency
50 47 .64select the renal artery, usually secondary to acute caudalangulation. These five patients underwent subsequent at-
tempts via the left brachial artery, four of which were
successful for a secondary technical success of 98%.
Embolic protection was used in 25 patients: 20 (33%)
of 59 gold-coated stents, and 5 (13%) of 38 steel stents.
The difference is statistically significant and reflects the fact
that the embolic protection device did not become avail-
able for our use until early 2002, midway through the
series.
Most arteries were treated with 4-, 5-, and 6-mm
stents, with no differences in stent diameter between the
gold-coated and stainless steel groups. Although slightly
more contrast was used on average in the stainless steel
group, the difference was not statistically significant (Table
III).
There were no perioperative deaths and no operative
conversions. Complications occurred in 6 patients (7.3%)
and did not differ by group. One minor complication
(1.2%) of a groin hematoma did not require operative
therapy or blood transfusion but did prolong hospital stay
by 1 day for observation. Five major complications (6.1%)
occurred:
● Postoperative azotemia (serum creatinine level in-
crease 20%) occurred in three patients (3.9%).
Azotemia resolved spontaneously in one patient and
after a stent was placed in a contralateral stenosis on
Table II. Characteristics of renal artery stenoses by
duplex and arteriography according to stent type—gold-
coated or stainless steel
Gold (n  59) Steel (n  38) P
Duplex
Peak systolic velocity (cm/s) 316  160 329  135 .71
Renal aortic ratio 4.4  2.4 5.0  2.6 .28
Resistive Index 0.80  0.1 0.81  0.1 .78
Arteriogram
Ostial location 85% 94% .14
Occlusions 2 1 NS
Systolic pressure gradient
(mm Hg)
52  31 58  40 .63
NS  Not significant.
Table III. Characteristics of renal artery stent procedures
by type of stent used—gold-coated or stainless steel
Gold (n59) Steel (n38) P
Stent diameter .96
3 mm 1.7% 2.7%
4 mm 10.1% 8.1%
5 mm 47.5% 51.4%
6 mm 40.7% 35.1%
7 mm 0.0% 2.7%
Stents per artery 1.03 1.08 .37
Fluoroscopy time (minutes) 31  20 36  23 .37
Contrast volume used (mL) 81  53 91  52 .42post-op day 1 in another. One patient with a baseline
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renal failure after a failed attempt at stenting through
femoral access. A stent was subsequently placed via a
left brachial approach but the patient did not improve
and went on to require dialysis.
● In one patient, a perinephric hematoma developed
after a parenchymal perforation with a guidewire. This
was detected by computed tomography scan after the
patient reported flank pain postoperatively. He was
transfused with 2 units of packed red blood cells and
was discharged on post-op day 5 without further inci-
dent.
● One patient had a myocardial infarction and required
urgent percutaneous transluminal angioplasty of a cor-
onary artery bypass graft stenosis.
Follow-up duplex data were available on 75 patients (96%)
and 92 arteries (95%). One patient was lost to follow-up.
Two patients died before follow-up duplex exams: one died
1 month post-op after a motor vehicle accident; the other,
who had extensive coronary and peripheral vascular disease,
died 4 months after renal artery stenting (1 month after a
below-knee amputation) presumably of myocardial infarc-
tion.
Follow-up ranged from 1 to 38months, with an overall
mean of 16 months (gold-coated stent group, 15 months;
stainless steel group, 18 months, NS). Mean duplex veloc-
ities in the steel and gold-coated stent groups at the preop-
erative, first follow-up at 1 month after operation, and at
the last follow-up visit, are depicted in Fig 1. The initial
peak systolic velocities at 1 month did not differ signifi-
cantly between the groups. At the last follow-up, velocities
were significantly higher in the gold-coated stent group
(229 cm/s vs 153 cm/s; P  .044, t test).
Overall, the 1-, 2- and 3-year life-table freedom from
restenosis was 75%, 55%, and 55%. In the stainless steel
stent group, the 1- and 2-year freedom from restenosis was
84% and 78%. In the gold-coated stent group, the 1- and
2-year freedom from restenosis was 69% and 39% (P 
Fig 1. Mean peak systolic velocities measured pre-op, 1-month
post-op, and at last follow-up (gold 15  4.5 months, steel 18 
7.5 months) in renal arteries treated with gold-coated and stainless
steel stents (*P .044, t test)..012, log-rank test) (Fig 2).By multivariate analysis, only bilateral disease (P 
.046; hazard ratio [HR], 2.3; 95% confidence interval [CI],
1.02 to 5.2) and gold coating (P .018; HR, 3.3; 95% CI,
1.2 to 8.7) were predictors of restenosis. By univariate
analysis, indication for treatment (hypertension or chronic
renal insufficiency), patient demographics (age, gender,
diabetes mellitus, tobacco use, coronary artery disease,
peripheral vascular disease, hypercholesterolemia, presence
of an abdominal aortic aneurysm), stent diameter (4, 5, or
6 mm), and use of embolic protection, did not correlate
with restenosis.
According to AHA criteria, patients in the stainless steel
group had better hypertension control than those treated
with a gold-coated stent. By life-table analysis, 87% of
patients in the stainless steel stent group had improved
blood pressure control at 1 year compared with 77% of
patients in the gold-coated stent group (P  .042, log
rank) (Fig 3). There were no significant differences in the
effect on serum creatinine levels between the two groups
Fig 2. Freedom from restenosis based on surveillance duplex
scanning according to stent type—gold-coated or stainless steel
(Kaplan-Meier method, standard error 10% throughout, num-
ber of patients at risk included with curves; P  .012, log rank).
Fig 3. Blood pressure improvement at last follow-up according
to stent type—gold-coated or stainless steel (Kaplan-Meier
method, standard error10% to 1-year, number of patients at risk
included with curves; P  .042, log rank).(Fig 4). The overall reintervention rate based on clinical
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DISCUSSION
The current study compared restenosis in NIRoyal
gold-coated stents with several stainless steel stents used to
treat atherosclerotic renal artery stenosis. Our results show
that a recurrent stenosis was 3.3 times more likely to
develop with the gold-coated NIRoyal stents and that
patients treated with gold-coated stents had worse hyper-
tension control than patients with stainless steel stents.
These findings are consistent with several prospective, ran-
domized studies demonstrating a higher rate of early (6-
month) restenosis and intimal hyperplasia in coronary ar-
teries treated with gold-coated versus noncoated stents:
● Park et al17 reported a nearly twofold higher incidence
of angiographic restenosis in 110 coronary arteries
randomized to receive gold-coated NIR stents. In this
study, there was a trend toward increased major ad-
verse cardiac events in the gold-coated stent group,
but the difference was not statistically significant (P 
.113).17
● In 103 patients randomized to receive gold-coated
coronary stents, vom Dahl et al15 demonstrated a 40%
greater loss of in-stent luminal diameter by follow-up
arteriography at 6 months. However, no differences
were noted in clinical outcomes between the two
groups in this study.15
● In a series of 700 randomized patients, Kastrati et
al16 reported a 1.3-fold higher incidence of angio-
graphic restenosis in gold-coated stents and a signifi-
cantly less-favorable event-free survival at 1 year (P 
.001).16
In contrast to these results in coronary arteries, a retro-
spective analysis by Zeller et al18 reported similar restenosis
rates in gold-coated and stainless steel stents used in the
treatment of 219 ostial renal artery stenosis.18 Gold-coated
Fig 4. Serum creatinine stable or improved at last follow-up
according to stent type—gold-coated or stainless steel (Kaplan-
Meier method, standard error10% to 1-year, number of patients
at risk included with curves).stents were placed in 29% of arteries and stainless steelstents in 71%. The authors found no significant difference
in the percentage of patients in the two groups who devel-
oped restenosis at 12 months (12.2% in gold coated stents,
11.1% in noncoated stents). However, restenosis was not
analyzed using life-table analysis technique, which is differ-
ent from our study. Also, the criteria used to determine
restenosis were not stated. It is possible that some asymp-
tomatic restenosis in the Zeller study were missed if routine
follow-up duplex scans or arteriography was not per-
formed. In the Zeller study, logistic regression found only
smaller stent diameter predicted restenosis. In our series,
no difference was found in restenosis in 4-, 5-, and 6-mm
stents using Cox regression.
Overall at our institution, renal duplex scanning is very
reliable in detecting renal artery stenosis. Although this was
not studied during the same time period of the current
series, it has been determined in a previous review using the
same criteria (renal-aortic ratio 3.5 or a peak systolic
velocity 200 cm/s). These data were submitted for the
laboratory’s Intersocietal Commission for the Accredita-
tion of Vascular Laboratories certification.
Comparison was performed between noninvasive du-
plex data and arteriographic evaluation of the same patients
from 1995 to 2000. For detection of a hemodynamically
significant (60%) stenosis by arteriogram, renal duplex
was 88% sensitive and 92% specific, with a positive predic-
tive value of 93%, a negative predictive value of 85%, and an
overall accuracy of 89%. The criteria for restenosis in the
current series were also based on duplex velocity measure-
ments.
Although data have suggested elevated duplex veloci-
ties in other stented arteries such as carotids, this was not
our experience in the renal arteries.22 Lower velocity crite-
ria were used in defining restenosis because our 1-month
postoperative data suggested that velocities are initially low
after stenting. The mean velocities at 1 month after stent
placement were 148 cm/s in the gold-coated group and
122 cm/s in the steel group (difference not significant)
(Fig 1).
Given the initial normalization of velocities, we be-
lieved that increasing velocities were a suggestive of reste-
nosis. For example, if a patient were to have an initial
post-op velocity of 140 and then return with a velocity of
190, we would consider that evidence of restenosis even
though the velocity did not reach the 200-cm/s cutoff that
is used in initial screening. The specific reason 180 cm/s
was chosen was that it is the only other velocity criteria
referenced in the literature for restenosis. This kept us
consistent with that report.9 To date, we have not found
any false-positives on repeat arteriography, although we
have yet not reintervened on all patients with recurrent
velocity elevations.
Patients with gold-coated stents were found to have
significantly worse blood pressure control by 1 year. Early
loss of blood pressure control is consistent with physiolog-
ically significant recurrent stenosis secondary to intimal
hyperplasia. Our reintervention rate did not differ between
the two groups, however.
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tomatic restenosis was conservative. Patients who had not
experienced obvious clinical deterioration but had resteno-
sis determined by a follow-up duplex scan were typically
watched and not taken for repeat angiography until symp-
toms had recurred. Thus, the finding of worse blood pres-
sure control in the gold-coated stent group suggests to us
that we should have intervened sooner in those patients
with duplex evidence of restenosis. Our group has subse-
quently becomemore aggressive about early reintervention
for restenosis, even in stable patients with restenosis deter-
mined from duplex exam alone.
One limitation of our series was that the stent strut
design was not the same for gold-coated and stainless steel
stents. It is thus possible that stent design, rather than gold
coating, caused the differences that we observed. However,
all the stents in the series, including the various stainless
steel stents, differed slightly in strut design, whereas the one
clear distinguishing characteristic of the NIRoyal stent is its
gold coating.
Biologically, the higher restenosis rate in gold-coated
stents has several possible explanations. Gold demonstrates
excellent resistance to corrosion in air, but its resistance in
the intravascular environment is approximately 100 times
less than that of high-grade stainless steel. In vitro studies
suggest that corrosion, leading to the diffusion of metal
ions into biologic tissues, initiates an inflammatory re-
sponse.23 Klein et al24 has shown that metal ions can
upregulate cellular adhesion molecules involved in intimal
hyperplasia. Gold also has a higher electronegative surface
charge than stainless steel.25 It is plausible that this differ-
ence may contribute to an enhanced cellular inflammatory
response within the media that acts as a stimulus for intimal
hyperplasia and restenosis.
Finally, it has been suggested the increased hyperplasia
in gold-coated NIR stents may be the result of a rougher
stent surface resulting from the manufacturing process of
applying the gold coating. Edelman et al14 found that in
porcine coronary arteries, the effect on hyperplasia could be
abrogated by heating gold-coated stents to alter the surface
finish. Although a refined heat treatment processes has
improved the surface smoothness of the NIRoyal stent,
texture may still have a role in restenosis.
Restenosis remains a significant challenge in the endo-
vascular management of symptomatic renal artery stenosis.
Despite this, RAS has largely replaced operative therapy
because of lower morbidity and mortality rates. As stent
designs evolve to improve technical success and reduce
complications and restenosis, it remains important to mon-
itor the results of various stent types, particularly those
coated with bioreactive substances.
In our series, gold-coated stents had a significantly
higher incidence of restenosis and led to a worsened clinical
outcome with respect to blood pressure control. Given
these results, further evaluation—ideally a prospective ran-
domized trial comparing gold-coated and stainless steel
stents for treatment of symptomatic renal artery steno-
sis—is warranted. We recommend that patients who havereceived gold-coated stents for the treatment of atheroscle-
rotic renal artery stenosis be followed closely for evidence of
restenosis.
REFERENCES
1. Gruntzig A, Kuhlmann U, Kaufman S. Treatment of renovascular
hypertension with percutaneous transluminal dilatation of a renal artery
stenosis. Lancet 1978;1:801-2.
2. Katzen B, Chang J, Lukowsky G, Abramson E. Percutanous translumi-
nal angioplasty for the treatment of renovascular hypertension. Radiol-
ogy 1979;131:53-8.
3. Tegtmeyer C, Kellum C, Ayers C. Percutaneous transluminal angio-
plasty of the renal artery. Results and long-term follow-up. Radiology
1984;153:77-84.
4. Weibull H, Tornquist C, Bergqvist D, Nyman U, Takolander R, Karls-
son S, et al. Reversible renal insufficiency after percutaneous translumi-
nal angioplasty (PTA) of renal artery stenosis. Acta Chir Scand 1984;
150:295-300.
5. Leertouwer TC, Gussenhoven EJ, Bosch JL, van Jaarsveld BC, van Dijk
LC,Deinum J, et al. Stent placement for renal arterial stenosis: where do
we stand? A meta-analysis. Radiology 2000;216:78-85.
6. Lederman R, Mendelsohn F, Santos R, Phillips H, Stack R, Crowley J.
Primary renal artery stenting: characteristics and outcomes after 363
procedures. Am H J 2001;142:314-23.
7. Bakker J, Goffette P, Henry M, Mali WP, Melki JP, Moss JG et al. The
Erasme Study: a multicenter study on the safety and technical results of
the Palmaz stent used for the treatment of atherosclerotic ostial renal
artery stenosis. Cardiovasc Intervent Radiol 1999;22:468-74.
8. Gill K, Fowler R. Atherosclerotic renal arterial stenosis: clinical out-
comes of stent placement for hypertension and renal failure. Radiology
2003;226:821-6.
9. Yutan E, Glickerman DJ, Caps MT, Hatsukami T, Harley JD, Kohler
TR, et al. Percutaneous transluminal revascularization for renal artery
stenosis: Veterans Affairs Puget Sound Health Care System experience.
J Vasc Surg 2001;34:685-93.
10. Bush R, Najibi S,MacDonaldM, Lin PH, Chaikof EL,Martin LG, et al.
Endovascular revascularization of renal artery stenosis: technical and
clinical results. J Vasc Surg 2001;33:1041-9.
11. van de Ven PJ, Kaatee R, Beutler JJ, Beek FJ, Woittiez AJ, Buskens E,
et al. Arterial stenting and balloon angioplasty in ostial atherosclerotic
renovascular disease: a randomised trial. The Lancet 1999;353:282-6.
12. Cognet F, Garcier JM,DranssartM,Defraissinette B, Cercueil JP, Ravel
A, et al. Percutaneous transluminal renal angioplasty in atheroma with
renal failure: long-term outcomes in 99 patients. Eur Radiol 2001;11:
2524-30.
13. Harding SA, McKenna CJ, Flapan AD, Boon NA. Long-term clinical
safety and efficacy of NIRoyal vs. NIR intracoronary stent. Cathet
Cardiovasc Interv 2001;54:141-5.
14. Hehrlein C,Metz J, EnsingerW, Kubler W. Influence of surface texture
and change on the biocompatibility of endovascular stents. Coron
Artery Dis 1995;6:581-6.
15. vom Dahl J, Haager PK, Grube E, Gross M, Beythien C, Kromer EP ,
et al. Effects of gold coating of coronary stents on neointimal prolifer-
ation following stent implantation. Am J Cardiol 2002;89:801-5.
16. Kastrati A, Schomig A, Dirschinger J, Mehilli J, von Welser N, Pache J,
et al. Increased risk of restenosis after placement of gold-coated stents:
results of a randomized trial comparing gold-coated with uncoated steel
stents in patients with coronary artery disease. Circulation 2000;101:
2478-83.
17. Park SJ, Lee CW, Hong MK, Kim JJ, Park SW, Tahk SJ, et al.
Comparison of gold-coated NIR stents with uncoated NIR stents in
patients with coronary artery disease. Am J Cardiol 2002;89:872-5.
18. Zeller T, Muller C, Frank U, Burgelin K, Sinn L, Horn B, et al. Gold
coating and restenosis after primary stenting of ostial renal artery
stenosis. Cathet Cardiovasc Interv 2003;60:1-60.
19. Rundback JH, Sacks D, Kent KC, Cooper C, Jones D, Murphy T, et al.
Guidelines for the reporting of renal artery revascularization in clinical
trials. J Vasc Interv Radiol 2002;13:959-74.
JOURNAL OF VASCULAR SURGERY
July 200546 Nolan et al20. Rundback JH, Sacks D, Kent KC, Cooper C, Jones D, Murphy T, et al.
Guidelines for the reporting of renal artery revascularization in clinical
trials. Circulation 2002;106:1572-1585.
21. Olin JW, Piedmonte MR, Young JR, DeAnna S, GrubbM, Childs MB.
The utility of duplex ultrasound scanning of the renal arteries for
diagnosing significant renal artery stenosis. Ann Intern Med 1995;122:
833-8.
22. Lal BK, Hobson I, Robert W., Goldstein J, Chakhtoura EY, Duran
WN.Carotid artery stenting: is there a need to revise ultrasound velocity23. Steinemann SG. Metal implants and surface reactions. Injury 1996;27:
sc16-22.
24. Klein CL, Nieder P, Wagner M, Kohler H, Bittinger F, Kirkpatrick CJ, et
al. The role of metal corrosion in inflammatory processes: induction of
adhesion molecules by heavy metal ions. J Materials Sci 1994;5:798-807.
25. Sprague EA, Palmaz JC, Simon C,Watson A. Electrostatic forces on the
surface of metals as measured by atomic force microscopy. J Long Term
Eff Med Implants 2000;10:111-25.criteria? J Vasc Surg 2004;39:58-66. Submitted Nov 30, 2004; accepted Mar 26, 2005.
Receive table of contents by e-mail
To receive the tables of contents by e-mail, sign up through our Web site at
http://www.mosby.com/jvs
Choose E-mail Notification
Simply type your e-mail address in the box and click the Subscribe button
Alternatively, you may send an e-mail message to majordomo@mosby.com
Leave the subject line blank and type the following as the body of your message:
subscribe jvs_toc
You will receive an e-mail to confirm that you have been added to the mailing list.
Note that TOC e-mails will be sent out when a new issue is posted to the Web site.
